Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Breast Cancer Therapeutics Market

Breast Cancer Therapeutics Market Trends

Report ID: GMI466
Published Date: Nov 2023
Report Format: PDF

Download Free Sample

Breast Cancer Therapeutics Market Trends

Initiation of breast cancer awareness and screening programs by the regional government authorities to curb the mortality rates associated with breast cancer is anticipated to prove conducive for the market expansion.

Breast cancer therapeutics are increasingly effective while treating breast cancer and delivers more than 90% survival probabilities, especially when the disease is diagnosed at an early stage. As per the NCBI article, in 2017, breast cancer screening programs aid in early detection, prevention of risk factors, optimal treatment to lower the morbidity, and promote survival rate.
Moreover, adoption of breast cancer awareness campaigns by public organizations is projected to promote the education regarding breast cancer and breast cancer therapeutics. For instance, the National Breast Cancer Foundation initiated “October as a Breast Cancer Awareness Month”, a campaign to drive awareness concerning the impact of breast cancer. Such initiatives are expected to encourage the diagnosed breast cancer patients to opt for optimal breast cancer therapeutics, further driving the survival rate of breast cancer therapeutics that is expected to drive the market demand.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global breast cancer therapeutics industry size was around USD 26.7 billion in 2022 and is expected to reach USD 54.7 billion by end of 2032, backed by the growing incidence of breast cancer.

The targeted therapy segment generated revenue of USD 19 billion in 2022 and is anticipating a substantial growth in coming years, attributed to its adaptability for combination with other treatments, the emergence of personalized approaches to enhance clinical outcomes, and continuous advancements.

North America breast cancer therapeutics industry is expected to grow at 6.8% through 2032, owing to the high incidence of breast cancer, steadily rising disease burden, and presence of major players in the region.

AstraZeneca plc, Eli Lilly & Co, Inc., Pfizer, Inc., Novartis AG, Amgen, F. Hoffmann La Roche AG, Merck & Co, Inc., Gilead Sciences, Inc., Eisai Co., Ltd., and Macrogenics, Inc.